TP53 and neoplasm: The majority of ESCC samples carry TP53 mutations on one allele concomitantly with a loss of heterozygosity on the other allele, thus resulting in biallelic TP53 inactivation, a genomic alteration permissive for consistent genomic instability that allows the survival of tumor cells with large genomic alterations.